Bankrupt DNA testing firm 23andMe to be purchased for $256m

Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns The drugmaker Regeneron Pharmaceuticals has agreed to buy the genetic testing firm 23andMe Holding for $256m through a bankruptcy auction, the companies announced on Monday. Regeneron said it will comply with 23andMe’s privacy policies and applicable...